PMID- 9375008
OWN - NLM
STAT- MEDLINE
DCOM- 19971215
LR  - 20191210
IS  - 0042-6822 (Print)
IS  - 0042-6822 (Linking)
VI  - 238
IP  - 1
DP  - 1997 Nov 10
TI  - Acyclovir blocks cytokine gene expression in trigeminal ganglia latently infected 
      with herpes simplex virus type 1.
PG  - 53-63
AB  - We have previously found that interleukin (IL)-2, IL-10, interferon (IFN)-gamma, 
      RANTES, and tumor necrosis factor (TNF)-alpha mRNA transcription remain elevated 
      in the trigeminal ganglia (TG) of herpes simplex virus type 1 (HSV-1) latently 
      infected mice up to 120 days postinoculation (p.i.). To determine if this 
      phenomenon was dependent on HSV-1 DNA replication after the establishment of 
      latency (i.e., reactivation), cytokine gene expression was compared in TG of 
      acyclovir-treated and untreated latently infected mice. Oral acyclovir treatment 
      (begun 16 days p.i.) had no effect on serum levels of total anti-HSV-1 
      antibodies. However, there was a significant reduction in the titer of antibody 
      specific for glycoprotein D and glycoprotein B but not glycoprotein H/L 120 days 
      PI in the acyclovir-treated compared to vehicle-treated mice. These differences 
      were not significant at earlier time points (i.e., days 34 and 60 p.i.). 
      Consistent with these findings, acyclovir had no effect on cytokine gene 
      expression in latently infected TG 35 and 60 days p.i. However, 120 days p.i., 
      IFN-gamma and TNF-alpha mRNA were approaching baseline levels in TG of 
      acyclovir-treated mice, but remained significantly elevated in untreated controls 
      (i.e., IFN-gamma mRNA levels were sixfold higher in TG of untreated mice). 
      Therefore, viral DNA replication appears to provide an antigenic stimulus for 
      persistent cytokine gene expression in latently infected TG.
FAU - Halford, W P
AU  - Halford WP
AD  - Department of Microbiology and Immunology, Louisiana State University Medical 
      Center, New Orleans 70112-1393, USA.
FAU - Gebhardt, B M
AU  - Gebhardt BM
FAU - Carr, D J
AU  - Carr DJ
LA  - eng
GR  - EY02377/EY/NEI NIH HHS/United States
GR  - NS35470/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Virology
JT  - Virology
JID - 0110674
RN  - 0 (Antibodies, Viral)
RN  - 0 (Antiviral Agents)
RN  - 0 (Cytokines)
RN  - 0 (DNA Primers)
RN  - X4HES1O11F (Acyclovir)
SB  - IM
MH  - Acyclovir/*pharmacology/therapeutic use
MH  - Analysis of Variance
MH  - Animals
MH  - Antibodies, Viral/blood
MH  - Antiviral Agents/*pharmacology/therapeutic use
MH  - Cell Line
MH  - Chlorocebus aethiops
MH  - Cytokines/*biosynthesis
MH  - DNA Primers
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Gene Expression Regulation/*drug effects
MH  - Herpes Simplex/blood/drug therapy/*immunology
MH  - Herpesvirus 1, Human/*physiology
MH  - Mice
MH  - Polymerase Chain Reaction
MH  - Transcription, Genetic/drug effects
MH  - Trigeminal Ganglion/*immunology/*virology
MH  - Virus Latency/*physiology
MH  - Virus Replication/drug effects
EDAT- 1997/12/31 00:00
MHDA- 1997/12/31 00:01
CRDT- 1997/12/31 00:00
PHST- 1997/12/31 00:00 [pubmed]
PHST- 1997/12/31 00:01 [medline]
PHST- 1997/12/31 00:00 [entrez]
AID - S0042-6822(97)98806-1 [pii]
AID - 10.1006/viro.1997.8806 [doi]
PST - ppublish
SO  - Virology. 1997 Nov 10;238(1):53-63. doi: 10.1006/viro.1997.8806.